These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 5093018

  • 1. [Substitution therapy of parkinsonism. Insufficient results with 3-0-methyldopa].
    Ajuriaguerra J, Gauthier G, Geissbuhler F, Simona B, Constantinidis J, Yanniotis G, Krassoievitch M, Eisenring J, Tissot R.
    Presse Med (1893); 1971 Jun 19; 79(30):1396. PubMed ID: 5093018
    [No Abstract] [Full Text] [Related]

  • 2. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F, Gaillard JM, Eisenring JJ, Krassoievitch M, Yanniotis G, Tissot R.
    Rev Eur Etud Clin Biol; 1972 Jan 19; 17(1):38-44. PubMed ID: 5041348
    [No Abstract] [Full Text] [Related]

  • 3. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N, Kito S, Yamamoto M, Itoga E, Kosaka K.
    Nihon Rinsho; 1974 Mar 19; 32(3):579-86. PubMed ID: 4859014
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G, de Ajuriaguerra J, Simona B, Constantinidis J, Eisenring JJ, Krassoievitch M, Yanniotis G, Tissot R.
    Rev Neurol (Paris); 1970 Nov 19; 123(5):297-319. PubMed ID: 5513630
    [No Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN.
    Neurology; 1970 Dec 19; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract] [Full Text] [Related]

  • 6. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD, Lee JE, McDowell F.
    Trans Am Neurol Assoc; 1971 Dec 19; 96():59-65. PubMed ID: 5159130
    [No Abstract] [Full Text] [Related]

  • 7. [Methyldopa and levodopa].
    Chang CP.
    Zhonghua Yi Xue Za Zhi; 1974 Dec 19; 7():439-41. PubMed ID: 4211508
    [No Abstract] [Full Text] [Related]

  • 8. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J, Kase JC, Mena I, Palacios E.
    Rev Med Chil; 1973 Jun 19; 101(6):452-5. PubMed ID: 4764560
    [No Abstract] [Full Text] [Related]

  • 9. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL, Ringel SP.
    Confin Neurol; 1973 Jun 19; 35(3):186-92. PubMed ID: 4712885
    [No Abstract] [Full Text] [Related]

  • 10. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J.
    Rev Neurol (Paris); 1970 Apr 19; 122(4):243-8. PubMed ID: 5472041
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J.
    Presse Med (1893); 1969 Apr 05; 77(17):619-22. PubMed ID: 5785081
    [No Abstract] [Full Text] [Related]

  • 12. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E, Mårtensson A.
    Scand J Rehabil Med; 1974 Apr 05; 6(2):89-93. PubMed ID: 4837060
    [No Abstract] [Full Text] [Related]

  • 13. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD, Duvoisin RC, Mendoza MR, Schear MJ, Barrett RE.
    Trans Am Neurol Assoc; 1971 Apr 05; 96():55-8. PubMed ID: 5159129
    [No Abstract] [Full Text] [Related]

  • 14. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M.
    Psychiatr Neurol Neurochir; 1971 Apr 05; 74(4):331-3. PubMed ID: 5146239
    [No Abstract] [Full Text] [Related]

  • 15. Brain dopamine and noradrenaline in 3 Parkinsonians deceased during L-dopa treatment.
    Buscaino GA, Jori A, Campanella G.
    Acta Neurol (Napoli); 1972 Apr 05; 27(6):537-44. PubMed ID: 4651485
    [No Abstract] [Full Text] [Related]

  • 16. [Therapy of parkinsonism using a combination of L-dopa and decarboxylase inhibitor].
    Völler GW, Muschard F.
    Med Welt; 1973 Apr 27; 24(17):705-7. PubMed ID: 4750934
    [No Abstract] [Full Text] [Related]

  • 17. [Parkinsonism. Therapeutic, pathophysiological, pharmacological and biochemical aspects].
    Dupont E.
    Ugeskr Laeger; 1973 Jan 15; 135(3):116-22. PubMed ID: 4567942
    [No Abstract] [Full Text] [Related]

  • 18. [What success does L-Dopa have in the treatment of parkinsonian akinesia?].
    Aebert K.
    Dtsch Med Wochenschr; 1967 Mar 17; 92(11):483-7. PubMed ID: 6019685
    [No Abstract] [Full Text] [Related]

  • 19. The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
    Sweet RD, McDowell FH.
    Adv Neurol; 1974 Mar 17; 5():331-8. PubMed ID: 4440581
    [No Abstract] [Full Text] [Related]

  • 20. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R.
    Presse Med (1893); 1969 Apr 05; 77(17):617-8. PubMed ID: 5785080
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.